Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults

The safety and immunogenicity of the MRK adenovirus type 5 (Ad5) HIV-1 clade B gag vaccine was assessed in an international Phase I trial. Three-hundred and sixty healthy HIV-uninfected adults were enrolled on five continents. Subjects received placebo or 1 × 10(9) or 1 × 10(10) viral particles (vp)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nicholson, Ouzama, DiCandilo, Fay, Kublin, James, Sun, Xiao, Quirk, Erin, Miller, Michelle, Gray, Glenda, Pape, Jean, Robertson, Michael N., Mehrotra, Devan V., Self, Steven, Turner, Katherine, Sanchez, Jorge, Pitisuttithum, Punnee, Duerr, Ann, Dubey, Sheri, Kierstead, Lisa, Casimiro, Danilo, Hammer, Scott M.
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc. 2011
Assuntos:
Vaccines
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3422055/
https://ncbi.nlm.nih.gov/pubmed/20854108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/aid.2010.0151
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados